VJHemOnc is committed to improving our service to you

ERIC 2020 | Developing and understanding kinase inhibitors to treat CLL

VJHemOnc is committed to improving our service to you

Dimitar Efremov

Dimitar Efremov, MD, PhD, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, discusses how kinase inhibitors have improved for the treatment of chronic lymphocytic leukemia (CLL) by blocking survival signals. However, some treatments are less effective and these differences need to be explored so they can be considered when designing novel therapies. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter